Stockscreener 앱 받기
0.3401
3.49%
-0.0123
시간 외 거래:
.34
-0.000100
-0.03%
전일 마감가:
$0.3524
열려 있는:
$0.3501
하루 거래량:
204.50K
Relative Volume:
0.36
시가총액:
$7.00M
수익:
$301.60K
순이익/손실:
$-8.22M
주가수익비율:
-0.6728
EPS:
-0.5055
순현금흐름:
$-5.05M
1주 성능:
-10.59%
1개월 성능:
-15.36%
6개월 성능:
-72.57%
1년 성능:
-73.22%
1일 변동 폭
$0.34
$0.3501
1주일 범위
$0.34
$0.39
52주 변동 폭
$0.3302
$2.00
Nexalin Technology Inc Stock (NXL) Company Profile
명칭
Nexalin Technology Inc
전화
(832) 260-0222
주소
1776 YORKTOWN, HOUSTON
Compare NXL vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NXL
Nexalin Technology Inc
|
0.3401 | 7.25M | 301.60K | -8.22M | -5.05M | -0.5055 |
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Nexalin Technology Inc 주식(NXL)의 최신 뉴스
Number of shareholders of Nexalin Technology, Inc. – NASDAQ:NXL - TradingView
Nexalin Technology, Inc. 1Q 2026: Revenue $14.95K, EPS ($0.11) — 10-Q Summary - TradingView
Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Nexalin Technology (NXL) Q1 loss, cash burn and Nasdaq bid-price warning - Stock Titan
Peer-Reviewed Neuroimaging Data Supports Nexalin’s Technology for Chronic Insomnia - Sleep Review
Nexalin Technology Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
MSN Money - MSN
NXL Stock Price, Quote & Chart | NEXALIN TECHNOLOGY INC (NASDAQ:NXL) - ChartMill
Nexalin reports sleep quality improvement in insomnia study By Investing.com - Investing.com South Africa
Nexalin reports sleep quality improvement in insomnia study - Investing.com
After 4 weeks, Nexalin insomnia study showed no sham-group sleep gain - Stock Titan
Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia - GlobeNewswire
Nexalin Technology appoints Justin Fleet as CFO - MSN
Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Quantisnow
Nexalin Technology appoints Justin Van Fleet as CFO - MSN
Nexalin Technology slides after pricing $5M stock offering - MSN
Nexalin announces pivotal insomnia trial, targets Q2 enrollment By Investing.com - Investing.com India
NXL Nexalin Technology Q4 2025 earnings narrowly miss consensus estimates, shares tick higher as investors overlook minor shortfall.Expert Entry Points - Xã Thanh Hà
Nexalin Advances Pivotal Insomnia Trial for HALO Clarity - The Globe and Mail
NXL (Nexalin Technology Inc.) reports narrow Q4 2025 EPS miss, shares rise 18 percent on positive investor sentiment.Binary Event - Cổng thông tin điện tử tỉnh Tây Ninh
Nexalin (NXL) funds 160-patient pivotal HALO Clarity insomnia trial - Stock Titan
Nexalin announces pivotal insomnia trial, targets Q2 enrollment - Investing.com
Nexalin Technology, Inc. to Advance Pivotal Clinical Trial for HALO™ Clarity Device Aimed at Treating Moderate-to-Severe Insomnia - Quiver Quantitative
Nexalin lines up 160-patient insomnia study to support FDA filing - Stock Titan
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment - The Manila Times
NXL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Nexalin Technology : Investor Presentation March 2026 - marketscreener.com
Nexalin Technology (NXL) Stock: Why Growth Investors Chase It (-2.65%) 2026-04-20Hedge Fund Inspired Picks - Cổng thông tin điện tử tỉnh Lào Cai
Is Nexalin Technology (NXL) stock failing at resistance | Nexalin Technology posts 4.8% EPS miss, wider loss vs estimatesPopular Market Picks - newser.com
Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China - Sahm
Nexalin Technology (NXL) Advances Alzheimer's Clinical Strategy - GuruFocus
Nexalin Technology Advances Global Clinical Strategy for Alzheimer’s Treatment Following Key FDA Meetings - Quiver Quantitative
After FDA and China meetings, Nexalin reshapes Alzheimer’s study - Stock Titan
Nexalin Technology Inc: Plans to Submit an Am - Moomoo
Nexalin Technology, Inc. Advances FDA Alzheimer?S Strategy and Designs FDA Application Amendments and U.S. Clinical Strategy Leveraging Extensive Real-World Neurostimulation Data Sets - marketscreener.com
Exclusive: Nexalin study flags reduced self-injury in adolescents using brain stimulation device - MSN
What to Know About Nexalin Technology (NXL) Stock Today (Institutional Demand) 2026-04-15Target Price - Cổng thông tin điện tử tỉnh Tây Ninh
Nexalin Hosts Live Investor Webinar and Q&A - National Today
Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21 - The Manila Times
Macro Review: Whats next for Nexalin Technology Inc Equity Warrant stock2026 Decliners & Fast Gain Stock Trading Tips - baoquankhu1.vn
Targets Report: Why is Nexalin Technology Inc Equity Warrant stock going upQuarterly Profit Summary & Daily Growth Stock Investment Tips - baoquankhu1.vn
Hedge Fund Moves: Is Nexalin Technology Inc still a buy after recent gains2026 Retail Activity & Low Drawdown Trading Strategies - baoquankhu1.vn
EXCLUSIVE: Nexalin Study Flags Reduced Self-Injury In Adolescents Using Brain Stimulation Device - Sahm
Are investors bearish on Nexalin Technology (NXL) Stock | Price at $0.39, Up 1.32%Stock Surge - newser.com
Hedge Fund Moves: What analysts say about Nexalin Technology Inc stock2026 Price Swings & Daily Price Action Insights - baoquankhu1.vn
Profit Review: Whats next for Nexalin Technology Inc Equity Warrant stock2026 Short Interest & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Nexalin Technology Inc (NXL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.34%
자본화:
|
볼륨(24시간):